Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mariana Vargas-Caballero, Sandrine Willaime-Morawek, Diego Gomez-Nicola, V. Hugh Perry, Diederik Bulters & Amrit Mudher. (2016) The use of human neurons for novel drug discovery in dementia research. Expert Opinion on Drug Discovery 11:4, pages 355-367.
Read now
Read now
Davide Seripa, Vincenzo Solfrizzi, Bruno P. Imbimbo, Antonio Daniele, Andrea Santamato, Madia Lozupone, Giovanni Zuliani, Antonio Greco, Giancarlo Logroscino & Francesco Panza. (2016) Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics 16:3, pages 259-277.
Read now
Read now
Articles from other publishers (31)
Abdul Jalil Shah, Roohi Mohi-ud-din, Saba Sabreen, Taha Umair Wani, Rafia Jan, Md. Noushad Javed, Prince Ahad Mir, Reyaz Hassan Mir & Mubashir Hussain Masoodi. (2023) Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's
Disease. Current Molecular Pharmacology 16:3, pages 254-279.
Crossref
Crossref
Kendall B.E. Moore, Ta-Jung Hung & Jessica S. Fortin. (2023) Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies. Drug Discovery Today 28:3, pages 103487.
Crossref
Crossref
Ji Hye Yoon, JooHyun Hwang, Sung Un Son, Junhyuk Choi, Seung-Won You, Hyunwoo Park, Seung-Yun Cha & Sungho Maeng. (2023) How Can Insulin Resistance Cause Alzheimer’s Disease?. International Journal of Molecular Sciences 24:4, pages 3506.
Crossref
Crossref
Antoine LeuzyShorena JanelidzeNiklas Mattsson-CarlgrenSebastian PalmqvistDirk JacobsClaudia Cicognola, Erik StomrudEugeen Vanmechelen, Jeffrey L. DageOskar Hansson. (2021) Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology 97:17.
Crossref
Crossref
Manlin Xu, Xia Zhang, Jing Yu, Zhiqing Guo, Ying Li, Xinying Song, Kang He, Guowei Li & Yucheng Chi. (2021) Proteome-Wide Analysis of Lysine 2-Hydroxyisobutyrylation in Aspergillus niger in Peanuts. Frontiers in Microbiology 12.
Crossref
Crossref
Sen Li, Yushan Yi, Ke Cui, Yanqiu Zhang, Yange Chen, Dou Han, Ling Sun, Xiaohui Zhang, Fei Chen, Yixin Zhang & Yufeng Yang. (2021) A Single-Chain Variable Fragment Antibody Inhibits Aggregation of Phosphorylated Tau and Ameliorates Tau Toxicity in vitro and in vivo. Journal of Alzheimer's Disease 79:4, pages 1613-1629.
Crossref
Crossref
Shuang Li, Xue‐Yuan Wu, Meng‐Yin Li, Shao‐Chuang Liu, Yi‐Lun Ying & Yi‐Tao Long. (2020) T232K/K238Q Aerolysin Nanopore for Mapping Adjacent Phosphorylation Sites of a Single Tau Peptide. Small Methods 4:11, pages 2000014.
Crossref
Crossref
Nicolas R. Barthélemy, Yan Li, Nelly Joseph-Mathurin, Brian A. Gordon, Jason Hassenstab, Tammie. L. S. Benzinger, Virginia Buckles, Anne M. Fagan, Richard J. Perrin, Alison M. Goate, John C. Morris, Celeste M. Karch, Chengjie Xiong, Ricardo Allegri, Patricio Chrem Mendez, Sarah B. Berman, Takeshi Ikeuchi, Hiroshi Mori, Hiroyuki Shimada, Mikio Shoji, Kazushi Suzuki, James Noble, Martin Farlow, Jasmeer Chhatwal, Neill R. Graff-Radford, Stephen Salloway, Peter R. Schofield, Colin L. Masters, Ralph N. Martins, Antoinette O’Connor, Nick C. Fox, Johannes Levin, Mathias Jucker, Audrey Gabelle, Sylvain Lehmann, Chihiro Sato, Randall J. Bateman & Eric McDade. (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nature Medicine 26:3, pages 398-407.
Crossref
Crossref
Giacomo Siano, Maria Claudia Caiazza, Ivana Ollà, Martina Varisco, Giuseppe Madaro, Valentina Quercioli, Mariantonietta Calvello, Antonino Cattaneo & Cristina Di Primio. (2019) Identification of an ERK Inhibitor as a Therapeutic Drug Against Tau Aggregation in a New Cell-Based Assay. Frontiers in Cellular Neuroscience 13.
Crossref
Crossref
Nima N. Naseri, Hong Wang, Jennifer Guo, Manu Sharma & Wenjie Luo. (2019) The complexity of tau in Alzheimer’s disease. Neuroscience Letters 705, pages 183-194.
Crossref
Crossref
Jeremy Koppel, Heidy Jimenez, Leslie Adrien, Eric H. Chang, Anil K. Malhotra & Peter Davies. (2019) Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model. Journal of Neurochemistry 148:1, pages 127-135.
Crossref
Crossref
Rocío Lajarín-Cuesta, Raquel L. Arribas, Carmen Nanclares, Eva M. García-Frutos, Luis Gandía & Cristóbal de los Ríos. (2018) Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection. European Journal of Medicinal Chemistry 157, pages 294-309.
Crossref
Crossref
Laura Kay, Ilse S. Pienaar, Ruwini Cooray, Gary Black & Meera Soundararajan. (2018) Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders. Molecular Neurobiology 55:9, pages 7352-7365.
Crossref
Crossref
Miguel Medina. (2018) An Overview on the Clinical Development of Tau-Based Therapeutics. International Journal of Molecular Sciences 19:4, pages 1160.
Crossref
Crossref
Jacques Hugon, François Mouton-Liger, Julien Dumurgier & Claire Paquet. (2017) PKR involvement in Alzheimer’s disease. Alzheimer's Research & Therapy 9:1.
Crossref
Crossref
Dmitriy V. Prokopovich, John W. Whittaker, Micaiah M. Muthee, Azka Ahmed & Luca Larini. (2017) Impact of Phosphorylation and Pseudophosphorylation on the Early Stages of Aggregation of the Microtubule-Associated Protein Tau. The Journal of Physical Chemistry B 121:9, pages 2095-2103.
Crossref
Crossref
Tingting Ku, Minjun Chen, Ben Li, Yang Yun, Guangke Li & Nan Sang. (2017)
Synergistic effects of particulate matter (PM
2.5
) and sulfur dioxide (SO
2
) on neurodegeneration via the microRNA-mediated regulation of tau phosphorylation
. Toxicology Research 6:1, pages 7-16.
Crossref
Crossref
S. Quraishe, C.M. Cowan & A. Mudher. 2017. Neuroprotection in Alzheimer's Disease. Neuroprotection in Alzheimer's Disease
73
96
.
Francesco Panza, Vincenzo Solfrizzi, Davide Seripa, Bruno P Imbimbo, Madia Lozupone, Andrea Santamato, Rosanna Tortelli, Ilaria Galizia, Camilla Prete, Antonio Daniele, Alberto Pilotto, Antonio Greco & Giancarlo Logroscino. (2016) Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy. Immunotherapy 8:9, pages 1119-1134.
Crossref
Crossref
Yingying Wu, Ningning Teng & Sen Li. (2016) Effects of macromolecular crowding and osmolyte on human Tau fibrillation. International Journal of Biological Macromolecules 90, pages 27-36.
Crossref
Crossref
Liviu‐Gabriel Bodea, Anne Eckert, Lars Matthias Ittner, Olivier Piguet & Jürgen Götz. (2016) Tau physiology and pathomechanisms in frontotemporal lobar degeneration. Journal of Neurochemistry 138:S1, pages 71-94.
Crossref
Crossref
Philip Lössl, Andrea M. Brunner, Fan Liu, Aneika C. Leney, Masami Yamashita, Richard A. Scheltema & Albert J. R. Heck. (2016) Deciphering the Interplay among Multisite Phosphorylation, Interaction Dynamics, and Conformational Transitions in a Tripartite Protein System. ACS Central Science 2:7, pages 445-455.
Crossref
Crossref
Jeremy Koppel, Heidy Jimenez, Leslie Adrien, Blaine S. Greenwald, Philippe Marambaud, Ezra Cinamon & Peter Davies. (2016) Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2:2, pages 121-130.
Crossref
Crossref
Chih-Hsin Lin, Yu-Shao Hsieh, Yih-Ru Wu, Chia-Jen Hsu, Hsuan-Chiang Chen, Wun-Han Huang, Kuo-Hsuan Chang, Hsiu Mei Hsieh-Li, Ming-Tsan Su, Ying-Chieh Sun, Guan-Chiun Lee & Guey-Jen Lee-Chen. (2016) Identifying GSK-3β kinase inhibitors of Alzheimer's disease: Virtual screening, enzyme, and cell assays. European Journal of Pharmaceutical Sciences 89, pages 11-19.
Crossref
Crossref
Miguel Medina, Félix Hernández & Jesús Avila. (2016) New Features about Tau Function and Dysfunction. Biomolecules 6:2, pages 21.
Crossref
Crossref
Guang-bin Zha, Mi Shen, Xiao-song Gu & Sheng Yi. (2016) Changes in microtubule-associated protein tau during peripheral nerve injury and regeneration. Neural Regeneration Research 11:9, pages 1506.
Crossref
Crossref
Francesco Panza, Vincenzo Solfrizzi, Davide Seripa, Bruno P. Imbimbo, Madia Lozupone, Andrea Santamato, Chiara Zecca, Maria Rosaria Barulli, Antonello Bellomo, Alberto Pilotto, Antonio Daniele, Antonio Greco & Giancarlo Logroscino. (2016) Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease. BioMed Research International 2016, pages 1-15.
Crossref
Crossref
Bess Frost, Farah H. Bardai & Mel B. Feany. (2016) Lamin Dysfunction Mediates Neurodegeneration in Tauopathies. Current Biology 26:1, pages 129-136.
Crossref
Crossref
M. Medina & J. Avila. 2016. Developing Therapeutics for Alzheimer's Disease. Developing Therapeutics for Alzheimer's Disease
327
341
.
Catherine M. Cowan, Shmma Quraishe, Sarah Hands, Megan Sealey, Sumeet Mahajan, Douglas W. Allan & Amritpal Mudher. (2015) Rescue from tau-induced neuronal dysfunction produces insoluble tau oligomers. Scientific Reports 5:1.
Crossref
Crossref
Miao-Kun Sun, Thomas J. Nelson & Daniel L. Alkon. (2015) Towards universal therapeutics for memory disorders. Trends in Pharmacological Sciences 36:6, pages 384-394.
Crossref
Crossref